A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase Ⅲ Trial on the Efficacy, Safety and Immunogenicity of Live-Attenuated Influenza Vaccine (LAIV)
Phase of Trial: Phase III
Latest Information Update: 18 Sep 2017
At a glance
- Drugs Influenza vaccine live attenuated (Nasovac-S) (Primary)
- Indications Influenza virus infections
- Focus Registrational; Therapeutic Use
- Sponsors Changchun BCHT Biotechnology
- 13 Sep 2017 Status changed from active, no longer recruiting to completed.
- 21 Jan 2017 Status changed from recruiting to active, no longer recruiting.
- 17 Nov 2016 New trial record